MARKET

KPRX

KPRX

KIORA PHARMACEUTICALS INC
NASDAQ
0.5896
-0.0094
-1.57%
After Hours: 0.5897 +0.0001 +0.02% 18:35 02/23 EST
OPEN
0.6090
PREV CLOSE
0.5990
HIGH
0.6090
LOW
0.5650
VOLUME
133.91K
TURNOVER
0
52 WEEK HIGH
6.41
52 WEEK LOW
0.4622
MARKET CAP
4.53M
P/E (TTM)
-0.1328
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at KPRX last week (0212-0216)?
Weekly Report · 6d ago
Kiora Pharmaceuticals Unveils Updated Investor Presentation
TipRanks · 02/12 22:33
Weekly Report: what happened at KPRX last week (0205-0209)?
Weekly Report · 02/12 11:38
HC Wainwright & Co. Maintains Buy Rating for Kiora Pharmaceuticals: Here's What You Need To Know
HC Wainwright & Co. Has maintained its Buy rating of Kiora Pharmaceuticals (NASDAQ:KPRX) and raise its price target from $3.50 to $2.00. The company's shares are trading down 0.84% over the last 24 hours at $0.66 per share.
Benzinga · 02/09 17:00
Kiora Pharmaceuticals: Strong Buy Rating on Strategic Partnership and Promising Trial Results
TipRanks · 02/09 11:16
HC Wainwright & Co. Maintains Buy on Kiora Pharmaceuticals, Adjusts Price Target To $2
Benzinga · 02/09 11:14
Kiora Pharmaceuticals (KPRX) Receives a Buy from Maxim Group
TipRanks · 02/07 12:57
5 Value Stocks To Watch In The Healthcare Sector
A value stock is traditionally defined in terms of how investors are valuing a company's future growth prospects. Low P/E multiples are good indicators that a company is undervalued. Value stocks in the healthcare sector include Kiora Pharmaceuticals, Voyager Therapeutics and Procaps Gr.
Benzinga · 02/05 14:44
More
About KPRX
Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of ophthalmic diseases. Its pipeline consists of three product candidates, including KIO-101, KIO-301, and KIO-201. Its lead product, KIO-301, is a vision-restoring small molecule that is designed to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases, including rheumatoid arthritis, and as such is termed the Ocular Presentation of Rheumatoid Arthritis and Other Autoimmune Diseases (OPRA+). KIO-101 is a next-generation, non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase. KIO-201 is a synthetic modified hyaluronic acid (HA) capable of coating the ocular surface and designed to resist degradation under conditions present in the eye.

Webull offers Kiora Pharmaceuticals Inc stock information, including NASDAQ: KPRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KPRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KPRX stock methods without spending real money on the virtual paper trading platform.